Can thalidomide improve outcome in patients with multiple myeloma?

被引：2
作者：
Richardson, Paul G.
Mitsiades, Constantine S.
Munshi, Nikhil C.
Anderson, Kenneth C.
机构：
[1] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[2] DFCI, Dept Med Oncol, Boston, MA USA
[3] DFCI, JLMMC, Boston, MA USA
[4] HMS, Boston, MA USA
[5] DFCI, Div Hematol Neoplasia, Boston, MA USA
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 11期
关键词：
chemotherapy; hematopoietic stem-cell transplantation; multiple myeloma; thalidomide;
D O I：
10.1038/ncponc0630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：590 / 591
页数：2
相关论文
共 8 条
  • [1] ATTAL M, 2006, BLOOD 0727
  • [2] Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
    Barlogie, B
    Tricot, G
    Rasmussen, E
    Anaissie, E
    van Rhee, F
    Zangari, M
    Fassas, A
    Hollmig, K
    Pineda-Roman, M
    Shaughnessy, J
    Epstein, J
    Crowley, J
    [J]. BLOOD, 2006, 107 (07) : 2633 - 2638
  • [3] To transplant or not to transplant?
    Munshi, NC
    Anderson, KC
    [J]. BLOOD, 2005, 106 (12) : 3687 - 3688
  • [4] Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
    Palumbo, A
    Bringhen, S
    Coravito, T
    Merla, E
    Capporella, V
    Callea, V
    Cangialosi, C
    Grasso, M
    Rossini, F
    Galli, M
    Catalano, L
    Zamagni, E
    Petrucci, MT
    De Stefano, V
    Ceccarelli, M
    Ambrosini, MT
    Avonto, I
    Falco, P
    Ciccone, G
    Liberati, AM
    Musto, P
    Boccadoro, M
    [J]. LANCET, 2006, 367 (9513) : 825 - 831
  • [5] Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
    Rajkumar, SV
    Blood, E
    Vesole, D
    Fonseca, R
    Greipp, PR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 431 - 436
  • [6] Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label Multicenter phase 2 study of efficacy, toxicity, and biological activity
    Richardson, P
    Schlossman, R
    Jagannath, S
    Alsina, M
    Desikan, R
    Blood, E
    Weller, E
    Mitsiades, C
    Hideshima, T
    Davies, F
    Doss, D
    Freeman, A
    Bosch, J
    Patin, J
    Knight, R
    Zeldis, J
    Dalton, W
    Anderson, K
    [J]. MAYO CLINIC PROCEEDINGS, 2004, 79 (07) : 875 - 882
  • [7] Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    Richardson, PG
    Schlossman, RL
    Weller, E
    Hideshima, T
    Mitsiades, C
    Davies, F
    LeBlanc, R
    Catley, LP
    Doss, D
    Kelly, K
    McKenney, M
    Mechlowicz, J
    Freeman, A
    Deocampo, R
    Rich, R
    Ryoo, JJ
    Chauhan, D
    Balinski, K
    Zeldis, J
    Anderson, KC
    [J]. BLOOD, 2002, 100 (09) : 3063 - 3067
  • [8] Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal, S
    Mehta, J
    Desikan, R
    Ayers, D
    Roberson, P
    Eddlemon, P
    Munshi, N
    Anaissie, E
    Wilson, C
    Dhodapkar, M
    Zeldis, J
    Barlogie, B
    Siegel, D
    Crowley, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) : 1565 - 1571
1